These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 10716688)

  • 1. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
    Schalm SW; Heathcote J; Cianciara J; Farrell G; Sherman M; Willems B; Dhillon A; Moorat A; Barber J; Gray DF
    Gut; 2000 Apr; 46(4):562-8. PubMed ID: 10716688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.
    Barbaro G; Zechini F; Pellicelli AM; Francavilla R; Scotto G; Bacca D; Bruno M; Babudieri S; Annese M; Matarazzo F; Di Stefano G; Barbarini G;
    J Hepatol; 2001 Sep; 35(3):406-11. PubMed ID: 11592603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
    Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP
    Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
    Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
    J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.
    Yalcin K; Degertekin H; Yildiz F; Celik Y
    Clin Infect Dis; 2003 Jun; 36(12):1516-22. PubMed ID: 12802750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
    Suh DJ; Lee HC; Byun KS; Cho M; Kweon YO; Tak WY; Chon CY; Koh KC; Lee YS
    Antivir Ther; 2013; 18(6):765-73. PubMed ID: 23900457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B.
    Vassiliadis T; Tziomalos K; Patsiaoura K; Zagris T; Giouleme O; Soufleris K; Grammatikos N; Theodoropoulos K; Mpoumponaris A; Dona K; Zezos P; Nikolaidis N; Orfanou-Koumerkeridou E; Balaska A; Eugenidis N
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1582-8. PubMed ID: 17683500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.